Differentially expressed long noncoding RNAs and mRNAs in PC12 cells under lysophosphatidylcholine stimulation

Wen Zhang, Su Dun, Ping Yin, Qingliang Wang, Tana Siqin, Aodong Tana, Si Qin, Xilinqiqige Bao, Alateng Qimuge, Tegexi Baiyin, Dezhi Yang, Siqin Bao, Seyin Baoyin, Wuhan QimugeScientific 2022 · DOI

TL;DR

This study investigates the impact of lysophosphatidylcholine (LPC) and nerve growth factor (NGF) on gene expression in PC12 cells, focusing on long noncoding RNAs (lncRNAs). They identified numerous novel lncRNAs and found that LPC significantly alters the expression of both lncRNAs and mRNAs, suggesting a role for these molecules in neuroprotection and neurodegenerative disease pathways.

What Problem Does This Paper Address?

Neurodegenerative diseases like Alzheimer's and Parkinson's are complex and their underlying molecular mechanisms are not fully understood. While long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in various cellular processes and diseases, their specific involvement in neuroprotection and neurodegenerative disease pathways, particularly in response to agents like lysophosphatidylcholine (LPC), remains largely unexplored. LPC has shown neuroprotective effects, but the molecular players mediating these effects, especially lncRNAs, are unknown. This paper aims to fill this knowledge gap by characterizing the lncRNA and mRNA expression profiles in PC12 cells under LPC and NGF stimulation.

Methods

The researchers employed high-throughput sequencing (Illumina HiSeq 4000) to analyze the transcriptome of PC12 cells. This involved:

  • RNA Extraction and Quality Control: Standard protocols were used to isolate total RNA, ensuring its purity and integrity.
  • RNA Sequencing: Libraries were prepared using a stranded RNA library prep kit, followed by paired-end sequencing.
  • Data Processing: Raw reads were filtered to obtain clean reads, which were then mapped to the rat reference genome.
  • Transcript Assembly and lncRNA Identification: Transcripts were assembled using Cufflinks, and lncRNAs were identified through a multi-step filtering process, including criteria for length, exon number, and coding potential prediction (using CPC, CNCI, and PFAM).
  • Differential Expression Analysis: Standard statistical methods were used to identify differentially expressed mRNAs and lncRNAs between treatment groups (control, LPC, NGF, and LPC+NGF).
  • KEGG Pathway Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on co-expressed genes to predict the biological functions of lncRNAs.
  • lncRNA-mRNA Network Analysis: Co-expression networks were constructed to identify potential interactions between lncRNAs and mRNAs.
  • Quantitative Real-Time PCR (qRT-PCR): This was used to validate the expression levels of selected differentially expressed lncRNAs and mRNAs.

Datasets

The study utilized PC12 cells treated with different conditions as the source of biological data. The sequencing data generated from these experiments were deposited in the NCBI GeneBank under the accession number PRJNA718985. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Novel lncRNAs in Neuroprotection: The study identified a significant number of novel lncRNAs in PC12 cells, suggesting that the lncRNA landscape in these cells is more complex than previously appreciated and that these novel lncRNAs might play crucial roles in cellular responses to neurotrophic factors.
  • LPC's Broad Impact: LPC, even at low concentrations, significantly alters the expression of both lncRNAs and mRNAs in PC12 cells. This indicates that LPC is not just a passive modulator but an active participant in cellular signaling pathways relevant to neuronal function.
  • Disease Pathway Enrichment: Differentially expressed mRNAs co-expressed with lncRNAs were found to be enriched in pathways associated with neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's. This strongly suggests a functional link between LPC-modulated lncRNAs and the pathogenesis of these conditions.
  • Complex lncRNA-mRNA Interactions: The lncRNA-mRNA network analysis revealed that individual lncRNAs can interact with a large number of mRNAs. This highlights the potential for lncRNAs to act as master regulators, coordinating the expression of multiple genes involved in complex cellular processes.
  • Potential Therapeutic Targets: The identification of specific lncRNAs (e.g., ENSRNOT00000082515) that interact with a substantial number of mRNAs involved in disease pathways points towards potential therapeutic targets for neurodegenerative diseases.

Key Results

  • Identification of lncRNAs: The study identified 564 annotated and 1077 novel lncRNAs in PC12 cells.
  • Differential Expression:
    • Under LPC stimulation, 121 lncRNAs were differentially expressed.
  • In PC12 cells treated with LPC, 483 mRNAs were differentially expressed.
  • NGF treatment led to 555 differentially expressed mRNAs and 122 differentially expressed lncRNAs.
  • Combined LPC and NGF treatment resulted in significant regulation of 1214 mRNAs and 227 lncRNAs compared to control.
  • Pathway Enrichment: KEGG analysis showed that co-expressed genes with annotated and novel lncRNAs were enriched in pathways such as ribosome, oxidative phosphorylation, Parkinson's disease, Huntington's disease, and Alzheimer's disease.
  • Key lncRNA: ENSRNOT00000082515 was identified as a highly interactive lncRNA, showing connections with 626 mRNAs.
  • Validation: qRT-PCR confirmed the differential expression of selected lncRNAs (ENSRNOT00000084874, ENSRNOT00000082515, LNC_001033) and mRNAs (Fgf18, Vcam1, Pck2), with Fgf18 and Pck2 showing increased expression and Vcam1 showing decreased expression under LPC treatment.

Limitations and Future Work

  • Mechanism of Action: While the study identifies differentially expressed lncRNAs and their co-expressed genes, the precise molecular mechanisms by which these lncRNAs regulate gene expression (e.g., transcriptional, post-transcriptional) are not fully elucidated. The authors suggest that lncRNAs might not always act through direct co-expression and propose investigating other functions for lncRNAs in regulating mitochondrial genes.
  • In Vivo Relevance: The study was conducted in vitro using PC12 cells. Future work should aim to validate these findings in more complex in vivo models to understand the physiological relevance of these lncRNAs in neurodegenerative disease progression and potential therapeutic interventions.
  • Functional Characterization: Further functional studies are needed to definitively establish the roles of the identified novel lncRNAs in neuroprotection and neurodegenerative disease pathways. This could involve knockdown or overexpression experiments.
  • Cross-talk between LPC and NGF: The study hints at a cross-talk between LPC and NGF, particularly in the combined treatment group. Further investigation into the synergistic or antagonistic effects of these factors on lncRNA and mRNA expression would be valuable.

Summary updated

Abstract

Lysophosphatidylcholine (LPC) was previously found to show neuroprotective effect on nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) induced signalings. Also, numerous studies reported the emerging roles of long noncoding RNAs (LncRNAs) involved in neurodegenerative disease. However, the biological mechanism of LPC and expression profile of lncRNAs has not been reported. Here, lncRNAs in PC12 cells under LPC and NGF treatment were analyzed using high throughput sequencing technology for the first time. We identified 564 annotated and 1077 novel lncRNAs in PC12 cells. Among them, 121 lncRNAs were differentially expressed in the PC12 cells under LPC stimulation. KEGG analysis showed that differentially expressed mRNAs co-expressed with lncRNAs mainly enriched in ribosome, oxidative phosphorylation, Parkinson's disease, Huntington's disease and Alzheimer's disease etc. LncRNA-mRNA network analysis showed that lncRNA ENSRNOT00000082515 had interactions with 626 different mRNAs suggesting that lncRNA ENSRNOT00000082515 probably play vital role. Finally, sequencing data were validated by qRT-PCR for ENSRNOT00000084874, ENSRNOT00000082515, LNC_001033 forward Fgf18, Vcam1, and Pck2.
BibTeX
@inproceedings{zhang2022differentially,
  author = {Wen Zhang and Su Dun and Ping Yin and Qingliang Wang and Tana Siqin and Aodong Tana and Si Qin and Xilinqiqige Bao and Alateng Qimuge and Tegexi Baiyin and Dezhi Yang and Siqin Bao and Seyin Baoyin and Wuhan Qimuge},
  title = {{Differentially expressed long noncoding RNAs and mRNAs in PC12 cells under lysophosphatidylcholine stimulation}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-21676-5},
}
Figure